• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Neutrophil-Rich Infusion Site Reactions After Continuous Subcutaneous Application of Foslevodopa/Foscarbidopa.

作者信息

Weise David, Haferkamp Sebastian

机构信息

Department of Neurology, Asklepios Fachklinikum Stadtroda, Stadtroda, Germany.

Department of Neurology, University of Leipzig, Leipzig, Germany.

出版信息

Mov Disord. 2025 Feb;40(2):389-390. doi: 10.1002/mds.30121. Epub 2025 Jan 11.

DOI:10.1002/mds.30121
PMID:39797706
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11832814/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3962/11832814/1aa0582986e7/MDS-40-389-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3962/11832814/1aa0582986e7/MDS-40-389-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3962/11832814/1aa0582986e7/MDS-40-389-g001.jpg

相似文献

1
Neutrophil-Rich Infusion Site Reactions After Continuous Subcutaneous Application of Foslevodopa/Foscarbidopa.持续皮下应用左旋多巴/卡比多巴后富含中性粒细胞的输注部位反应
Mov Disord. 2025 Feb;40(2):389-390. doi: 10.1002/mds.30121. Epub 2025 Jan 11.
2
Safety and efficacy of continuous subcutaneous foslevodopa-foscarbidopa in patients with advanced Parkinson's disease: a randomised, double-blind, active-controlled, phase 3 trial.晚期帕金森病患者连续皮下注射左多巴-卡比多巴的安全性和有效性：一项随机、双盲、阳性对照、3 期临床试验。
Lancet Neurol. 2022 Dec;21(12):1099-1109. doi: 10.1016/S1474-4422(22)00400-8.
3
Foslevodopa/Foscarbidopa: A Review in Advanced Parkinson's Disease.左旋多巴/卡比多巴肠凝胶：晚期帕金森病的综述
CNS Drugs. 2025 Jun;39(6):621-632. doi: 10.1007/s40263-025-01179-3. Epub 2025 Apr 8.
4
Reply to: "Neutrophil-Rich Infusion Site Reactions after Continuous Subcutaneous Application of Foslevodopa/Foscarbidopa".回复：“持续皮下应用福司来沃多巴/福司卡比多巴后富含中性粒细胞的输注部位反应”
Mov Disord. 2025 Feb;40(2):391-392. doi: 10.1002/mds.30120. Epub 2025 Jan 11.
5
Continuous Subcutaneous Foslevodopa/Foscarbidopa in Parkinson's Disease: Safety and Efficacy Results From a 12-Month, Single-Arm, Open-Label, Phase 3 Study.帕金森病患者皮下持续输注左旋多巴/卡比多巴：一项为期12个月的单臂、开放标签3期研究的安全性和有效性结果
Neurol Ther. 2023 Dec;12(6):1937-1958. doi: 10.1007/s40120-023-00533-1. Epub 2023 Aug 26.
6
Foslevodopa/Foscarbidopa Is Well Tolerated and Maintains Stable Levodopa and Carbidopa Exposure Following Subcutaneous Infusion.福司列弗多巴/福卡比多巴经皮下输注后具有良好的耐受性，并能维持稳定的左旋多巴和卡比多巴暴露量。
J Parkinsons Dis. 2021;11(4):1695-1702. doi: 10.3233/JPD-212813.
7
Metabolite profiling of foslevodopa/foscarbidopa in plasma of healthy human participants by LC-HRMS indicates no major differences compared to administration of levodopa/carbidopa intestinal gel.采用 LC-HRMS 对健康人体参与者血浆中的 foslevodopa/foscarbidopa 进行代谢物分析，结果表明与给予左旋多巴/卡比多巴肠凝胶相比无明显差异。
Pharmacol Res Perspect. 2024 Apr;12(2):e1190. doi: 10.1002/prp2.1190.
8
Comparability of Foslevodopa/Foscarbidopa Pharmacokinetics in Healthy Asian and White Participants.福沙左旋多巴/福沙卡比多巴在健康亚洲和白人受试者中药代动力学的可比性
Clin Pharmacol Drug Dev. 2023 Apr;12(4):407-415. doi: 10.1002/cpdd.1201. Epub 2022 Nov 16.
9
Continuous Subcutaneous Foslevodopa-Foscarbidopa in Parkinson's Disease: A Mini-Review of Current Scope and Future Outlook.帕金森病中持续皮下注射左多巴-卡比多巴：当前范围和未来展望的小型综述。
Mov Disord Clin Pract. 2024 Oct;11(10):1188-1194. doi: 10.1002/mdc3.14161. Epub 2024 Jul 11.
10
Licensed Subcutaneous Infusion Therapies in Advanced Parkinson's Disease: An Indirect Treatment Comparison and Cost-Minimisation Analysis.晚期帕金森病的皮下输注许可治疗：间接治疗比较与成本最小化分析
Neurol Ther. 2025 Jul 8. doi: 10.1007/s40120-025-00789-9.

引用本文的文献

1
Real-world experience with continuous subcutaneous foslevodopa/foscarbidopa infusion: insights and recommendations.持续皮下注射左旋多巴/卡比多巴乙酯的真实世界经验：见解与建议。
J Neural Transm (Vienna). 2025 Mar 22. doi: 10.1007/s00702-025-02911-5.

本文引用的文献

1
Skin Inflammatory Reactions in Patients with Continuous Subcutaneous Injection of Foslevodopa-Foscarbidopa Hydrate: Histopathology.持续皮下注射水合左旋多巴-卡比多巴患者的皮肤炎症反应：组织病理学
Mov Disord. 2025 Feb;40(2):378-379. doi: 10.1002/mds.30069. Epub 2024 Nov 19.
2
Continuous subcutaneous foslevodopa/foscarbidopa infusion for the treatment of motor fluctuations in Parkinson's disease: Considerations for initiation and maintenance.持续皮下输注左旋多巴/卡比多巴用于治疗帕金森病的运动波动：起始和维持的注意事项
Clin Park Relat Disord. 2024 Feb 10;10:100239. doi: 10.1016/j.prdoa.2024.100239. eCollection 2024.
3
Continuous Subcutaneous Foslevodopa/Foscarbidopa in Parkinson's Disease: Safety and Efficacy Results From a 12-Month, Single-Arm, Open-Label, Phase 3 Study.
帕金森病患者皮下持续输注左旋多巴/卡比多巴：一项为期12个月的单臂、开放标签3期研究的安全性和有效性结果
Neurol Ther. 2023 Dec;12(6):1937-1958. doi: 10.1007/s40120-023-00533-1. Epub 2023 Aug 26.
4
Safety and efficacy of continuous subcutaneous foslevodopa-foscarbidopa in patients with advanced Parkinson's disease: a randomised, double-blind, active-controlled, phase 3 trial.晚期帕金森病患者连续皮下注射左多巴-卡比多巴的安全性和有效性：一项随机、双盲、阳性对照、3 期临床试验。
Lancet Neurol. 2022 Dec;21(12):1099-1109. doi: 10.1016/S1474-4422(22)00400-8.
5
Treatment of subcutaneous nodules after infusion of apomorphine; a biopsy-controlled study comparing 4 frequently used therapies.阿朴吗啡输注后皮下结节的治疗：4 种常用疗法的活检对照研究。
Parkinsonism Relat Disord. 2021 Aug;89:38-40. doi: 10.1016/j.parkreldis.2021.06.024. Epub 2021 Jun 29.